Charles River Laboratories International, Inc. (CRL) Q4 FY25 Earnings Call

Fourth-quarter bookings improved, but 2026 growth depends on delayed DSA conversion and cost savings offsetting near-term headwinds.

Q4 FY25 results, source: company transcript and SEC filings
QuarterQ4 FY25
Call date2026-02-19
Length84 minutes
EPS$2.39
EPS consensus$2.33
Revenue$994.2M
Revenue consensus$987.0M

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

Other quarters: Q2 FY25

All CRL earnings ยท Back to CRL overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.